Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 3
2005 3
2006 1
2009 2
2010 1
2013 1
2019 1
2020 4
2021 12
2022 22
2023 16
2024 12
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Differences in IgG autoantibody Fab glycosylation across autoimmune diseases.
Koers J, Sciarrillo R, Derksen NIL, Vletter EM, Fillié-Grijpma YE, Raveling-Eelsing E, Graça NAG, Leijser T, Pas HH, Laura van Nijen-Vos L, Braham MVJ, Buisman AM, de Jong J, Schriek AI, Tio-Gillen AP, Teng YKO, Steenhuis M, Swaneveld FH, de Taeye SW, van Gils MJ, Verschuuren JJGM, Rutgers B, Heeringa P, Horváth B, Jacobs BC, de Leeuw K, Franssen CFM, Veyradier A, Coppo P, Gelderman KA, Marieke van Ham S, van Els CACM, van der Woude D, Huizinga R, Huijbers MG, Kuijpers TW, Toes REM, Bos NA, Rispens T; T2B Consortium. Koers J, et al. Among authors: steenhuis m. J Allergy Clin Immunol. 2023 Jun;151(6):1646-1654. doi: 10.1016/j.jaci.2022.10.035. Epub 2023 Jan 27. J Allergy Clin Immunol. 2023. PMID: 36716825
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Valk AM, Keijser JBD, van Dam KPJ, Stalman EW, Wieske L, Steenhuis M, Kummer LYL, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Horváth B, Hijnen DJ, Schreurs CRG, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Keijzer S, Derksen NIL, van Deelen M, van Mierlo G, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A, Rispens T; T2B! Immunity against SARS‐CoV‐2 study group. Valk AM, et al. Among authors: steenhuis m. Allergy. 2024 Jul;79(7):1952-1961. doi: 10.1111/all.16089. Epub 2024 Mar 4. Allergy. 2024. PMID: 38439527
Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection.
Keijzer S, Oskam N, Ooijevaar-de Heer P, Steenhuis M, Keijser JBD, Wieske L, van Dam KPJ, Stalman EW, Kummer LYL, Boekel L, Kuijpers TW, Ten Brinke A, van Ham SM, Eftimov F, Tas SW, Wolbink GJ, Rispens T. Keijzer S, et al. Among authors: steenhuis m. Front Immunol. 2024 Feb 29;15:1314507. doi: 10.3389/fimmu.2024.1314507. eCollection 2024. Front Immunol. 2024. PMID: 38487524 Free PMC article. Review.
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.
Stalman EW, Wieske L, Keijser JBD, van Dam KPJ, Kummer LYL, Wilbrink MF, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Onno Teng YK, van Paassen P, Busch MH, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Cristianawati O, Brinke AT, Verstegen NJM, Zwinderman KAH, van Ham SM, Rispens T, Welkers MR, Jonges M, Eftimov F, Kuijpers TW; T2B! immunity against SARS-CoV-2 study group. Stalman EW, et al. Among authors: steenhuis m. J Allergy Clin Immunol. 2024 Sep;154(3):754-766.e7. doi: 10.1016/j.jaci.2024.04.031. Epub 2024 May 17. J Allergy Clin Immunol. 2024. PMID: 38763170 Free article.
Saliva SARS-CoV-2 Antibody Prevalence in Children.
Keuning MW, Grobben M, de Groen AC, Berman-de Jong EP, Bijlsma MW, Cohen S, Felderhof M, de Groof F, Molanus D, Oeij N, Rijpert M, van Eijk HWM, Koen G, van der Straten K, Oomen M, Visser R, Linty F, Steenhuis M, Vidarsson G, Rispens T, Plötz FB, van Gils MJ, Pajkrt D. Keuning MW, et al. Among authors: steenhuis m. Microbiol Spectr. 2021 Oct 31;9(2):e0073121. doi: 10.1128/Spectrum.00731-21. Epub 2021 Sep 15. Microbiol Spectr. 2021. PMID: 34523985 Free PMC article.
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses.
van den Dijssel J, Duurland MC, Konijn VA, Kummer LY, Hagen RR, Kuijper LH, Wieske L, van Dam KP, Stalman EW, Steenhuis M, Geerdes DM, Mok JY, Kragten AH, Menage C, Koets L, Veldhuisen B, Verstegen NJ, van der Schoot CE, van Esch WJ, D'Haens GR, Löwenberg M, Volkers AG, Rispens T, Kuijpers TW, Eftimov F, van Gisbergen KP, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group. van den Dijssel J, et al. Among authors: steenhuis m. J Autoimmun. 2024 Apr;144:103175. doi: 10.1016/j.jaut.2024.103175. Epub 2024 Feb 21. J Autoimmun. 2024. PMID: 38387105 Free article.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
Verstegen NJM, Hagen RR, Kreher C, Kuijper LH, Dijssel JVD, Ashhurst T, Kummer LYL, Palomares Cabeza V, Steenhuis M, Duurland MC, Jongh R, Schoot CEV, Konijn VAL, Mul E, Kedzierska K, van Dam KPJ, Stalman EW, Boekel L, Wolbink G, Tas SW, Killestein J, Rispens T, Wieske L, Kuijpers TW, Eftimov F, van Kempen ZLE, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group. Verstegen NJM, et al. Among authors: steenhuis m. J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):855-864. doi: 10.1136/jnnp-2023-332224. J Neurol Neurosurg Psychiatry. 2024. PMID: 38548324 Free PMC article.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, Roosen J, van Kempen ZLE, Killestein J, Volkers AG, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Sanchez AP, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Cristianawati O, Rispens T, Brinke AT, Verstegen NJM, Marieke van Ham S, Tas SW, Kuijpers TW, Eftimov F; T2B! Immunity against SARS-CoV-2 study group. van Dam KPJ, et al. Among authors: steenhuis m. J Autoimmun. 2023 Feb;135:102984. doi: 10.1016/j.jaut.2022.102984. Epub 2023 Jan 2. J Autoimmun. 2023. PMID: 36621174 Free PMC article.
Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study.
Bouwmans P, Malahe SRK, Messchendorp AL, Vart P, Imhof C, Sanders JF, Gansevoort RT, de Vries APJ, Abrahams AC, Bemelman FJ, Vervoort JPM, Hilbrands LB, Ten Dam MAGJ, van den Dorpel RMA, Rispens T, Steenhuis M, Reinders MEJ, Hemmelder MH; RECOVAC Consortium. Bouwmans P, et al. Among authors: steenhuis m. Int J Infect Dis. 2024 May;142:106990. doi: 10.1016/j.ijid.2024.106990. Epub 2024 Feb 28. Int J Infect Dis. 2024. PMID: 38428480 Free article.
68 results